DOI

Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer

Retrieved on: 
星期四, 五月 9, 2024
SNF, FOLFIRINOX, DOI, Blood, Pancreatic cancer, Poster, TILS, Immunotherapy, TSX, PR, MD, Tumor microenvironment, AB, ONC, Roche, PDAC, Cancer, Patient, Pancreatic Cancer Action Network, AIO, Medicine, SWI, MMSc, Ethics, PD, Therapy, SAN, Anal cancer, TME, Pharmaceutical industry

SAN DIEGO and CALGARY, AB, May 9, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, will commence enrollment into a new GOBLET study pancreatic cancer cohort following both German regulatory and ethics approvals. This cohort will evaluate pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX) with or without the PD-L1 immune checkpoint inhibitor atezolizumab (Tecentriq®) in newly diagnosed patients with pancreatic ductal adenocarcinoma (PDAC). It is supported by a US$5M Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN), an innovative program established to accelerate the development of new treatments for pancreatic cancer. The chemotherapy regimens of mFOLFIRINOX or gemcitabine + nab-paclitaxel are the two most common standards of care for pancreatic cancer.1 Oncolytics has already reported data with the combination of gemcitabine and nab-paclitaxel (link to the PR, link to the poster) that surpassed historical outcomes.2-5 Positive results from a combination with mFOLFIRINOX could greatly enhance pelareorep's potential in addressing pancreatic cancer.

Key Points: 
  • This cohort will evaluate pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX) with or without the PD-L1 immune checkpoint inhibitor atezolizumab (Tecentriq®) in newly diagnosed patients with pancreatic ductal adenocarcinoma (PDAC).
  • It is supported by a US$5M Therapeutic Accelerator Award from the Pancreatic Cancer Action Network (PanCAN), an innovative program established to accelerate the development of new treatments for pancreatic cancer.
  • "Oncolytics is pleased to announce receipt of regulatory clearance to initiate the mFOLFIRINOX cohort in patients with newly diagnosed metastatic PDAC.
  • "We believe that working with PanCAN will help to further enrich Oncolytics' clinical relationships with the pancreatic cancer community.

EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments

Retrieved on: 
星期三, 五月 8, 2024
Science, FDA, AMD, Investment, DOI, Safety, OIS, Stuart, Florida, Food, Research, Cleveland Clinic, Growth, FACS, KOL, Therapy, Thomas Jefferson University, Eye, Wills Eye Hospital, Marketing, DME, Clinical trial, Associate, Diabetic retinopathy, ARVO, Plasma, Uveitis, Pharmaceutical industry

WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the first quarter ended March 31, 2024, and highlighted recent corporate developments.

Key Points: 
  • The Company plans to provide an update on the path forward for DURAVYU as a potential treatment in NPDR following a review of the full 12-month data in the third quarter of 2024.
  • EyePoint plans to host an R&D Day on June 26, 2024 in New York City.
  • Net product revenue for the first quarter was $0.7 million, compared to net product revenues for the first quarter ended March 31, 2023 of $7.4 million.
  • Operating expenses for the first quarter ended March 31, 2024 totaled $45.0 million versus $29.2 million in the prior year period.

Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101: a First-in-Class Epigenome Editing approach for the Treatment of LAMA2-deficient congenital muscular dystrophy (LAMA2-CMD)

Retrieved on: 
星期二, 五月 7, 2024
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Dicarboxylic acid, Metadata, DSM-IV codes, CRISPR, DOI, Safety, LAMA1, LAMA2, AAV, Tokyo Stock Exchange, DNA, Therapy, Patient, Congenital muscular dystrophy, Gene expression, Manuscript, BioRxiv, Vaccine

The company reported data demonstrating exceptional durability, robust efficacy and safety in dyW mouse disease model of LAMA2-CMD and in adult and juvenile NHPs.

Key Points: 
  • The company reported data demonstrating exceptional durability, robust efficacy and safety in dyW mouse disease model of LAMA2-CMD and in adult and juvenile NHPs.
  • LAMA2-CMD is a severe, early onset congenital muscular dystrophy caused by the absence of the LAMA2 protein.
  • No approved therapies to address the root cause of this condition exist or are in clinical trials.
  • "We are thrilled to post our comprehensive preclinical data supporting the development of MDL-101 on bioRxiv.

Boehringer Ingelheim receives Health Canada approval for SENVELGO™, the once-daily liquid oral solution for newly diagnosed diabetes in cats

Retrieved on: 
星期二, 五月 7, 2024
Hyperglycemia, Insulin, DOI, Boehringer Ingelheim, Pet, Veterinarian, Health, Animal, Research, SJM, Diabetes, Health Canada, Trigger, Vaccine, Farmer, Needle, Cat, Human, Veterinary medicine, Livestock, Food, Diagnosis, Boehringer, Diabetes in cats, Euthanasia, Horse, Report

SENVELGO™ (velagliflozin oral solution) is the first once-daily liquid oral solution to improve glycemic control in newly diagnosed cats with diabetes mellitus.

Key Points: 
  • SENVELGO™ (velagliflozin oral solution) is the first once-daily liquid oral solution to improve glycemic control in newly diagnosed cats with diabetes mellitus.
  • SENVELGO™ is the first once-daily liquid oral solution for the reduction of hyperglycemia in cats with non-insulin-dependent diabetes mellitus.
  • Pet owners can give the once-daily liquid oral solution with a small amount of food or directly into the cat's mouth.
  • Dr. Walt Ingwersen, Technical Services Veterinarian with Boehringer Ingelheim Canada, said SENVELGO™ revolutionizes the treatment and management of feline diabetes in newly diagnosed cats.

The geko™ device is now available through the NHS Supply Chain

Retrieved on: 
星期三, 五月 1, 2024
Leg, Supply, Pain, Patient, Knee, Cancer, BMJ Open, NHS, Acceleration, Calf, DOI, Hope, National Health Service, Hospital, Skin, PMID, SOC, Recurrence, Common fibular nerve, Carbon, INT, IWJ, Quality-adjusted life year, Mouth ulcer, Nursing, Health, Cardiovascular disease, Standard of care, Wound healing, RCT, Life imprisonment, Quality of life, Anxiety

HIGH WYCOMBE, England, May 1, 2024 /PRNewswire/ -- UK-based medical device manufacturer Firstkind Ltd, a subsidiary of Sky Medical Technology Ltd, today announced the geko device is available through the UK NHS Supply Chain. The Supply Chain manages the sourcing, delivery and supply of healthcare products and services for NHS trusts and healthcare organisations across England and Wales.

Key Points: 
  • HIGH WYCOMBE, England, May 1, 2024 /PRNewswire/ -- UK-based medical device manufacturer Firstkind Ltd, a subsidiary of Sky Medical Technology Ltd, today announced the geko device is available through the UK NHS Supply Chain .
  • The Supply Chain manages the sourcing, delivery and supply of healthcare products and services for NHS trusts and healthcare organisations across England and Wales.
  • "We're delighted to be listed on the NHS Supply Chain," said Bernard Ross, CEO and Founder of Sky Medical Technology.
  • Now with this wider access, through the NHS Supply Chain, geko device ease of ordering will further help NHS wound care nurses reduce the time managing wounds."

Genscience and Deerfield Management Announce Nature Publication Reporting Positive Impact of Genetic Evidence to Aid Discovery of More Effective Drug Targets

Retrieved on: 
星期三, 四月 17, 2024
Drug design, Probability, DOI, Broad Institute, Hematology, Health, Doctor of Philosophy, Disease, Human, Partner (business rank), EV, Optimism, Drug development, Drug discovery, Biotechnology, Gene, Pharmaceutical industry

NEW YORK, April 17, 2024 /PRNewswire/ -- Genscience LLC, a company applying genetic evidence and proprietary platforms for drug discovery and development and an affiliate of Deerfield Management Company ("Deerfield"), a healthcare investment firm, today announced a new study that shows incorporating genetic evidence into drug design significantly increases the probability of successful development by up to 2.6 times compared to when genetic evidence is absent. The new study appeared in the April 17, 2024 issue of the peer-reviewed journal Nature.¹ The study also documents new findings regarding how different characteristics of genetic evidence impact drug development success.

Key Points: 
  • The new study appeared in the April 17, 2024 issue of the peer-reviewed journal Nature .¹ The study also documents new findings regarding how different characteristics of genetic evidence impact drug development success.
  • "These findings further demonstrate that genetic evidence is the most effective means to improve drug discovery and development success rates and R&D efficiency," said Matt Nelson, PhD, Chief Executive Officer of Genscience and Vice President of Genetics and Genomics, Deerfield Discovery and Development (3DC).
  • "This new data helps illustrate the power of genetic evidence to enrich our understanding of the relationship between a potential drug target and the disease we seek to treat."
  • Increasing emphasis on drug mechanisms with supporting genetic evidence is expected to increase success rates and lower the cost of drug discovery and development.

EQS-News: HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell

Retrieved on: 
星期三, 四月 10, 2024
Liver, Liver failure, DOI, Cell death, Regeneration, Clinical professor, Colorectal cancer, Transplant, Hepatectomy, Risk, Patient, MKK4, Mayo Clinic, Manuscript, Liver transplantation, Teaching hospital, Human, MAP, Liver regeneration, Hepatocyte, PHLF, Regenerative medicine, Safety, Hepatology, Liver disease, Dietary supplement

HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).

Key Points: 
  • HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).
  • "The positive results in terms of safety and tolerability confirm our intention to soon offer a drug that has the potential to revolutionize the treatment of severe liver diseases.
  • The data pave the way for further Phase II studies evaluating the efficacy of HRX-215 in humans," emphasizes Dr. Wolfgang Albrecht, COO of HepaRegeniX.
  • Further, HRX-215 was also able to protect hepatocytes from cell death in a model for acute liver injury.

Tellbio’s Technology Demonstrates that Analysis of Circulating Tumor Cells Can Predict Survival Among Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Radium-2230

Retrieved on: 
星期三, 三月 27, 2024
OS, Harvard Medical School, DOI, Radium-223, Prostate cancer, Gene expression, Metastasis, Doctor of Pharmacy, JCO, Assistant, Patient, Tap, Biomarker, RNA, Chinese, Quality of life, CRPC, Senior, Hospital, Prognosis, CTC, Radiation therapy, PSA, FDA, CTCM, Medical imaging

ANDOVER, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- TellBio, Inc., a development-stage medical technology company focused on revolutionizing the detection of cancer metastasis through its unique and proprietary circulating tumor cell (CTC) technology, the TellDx CTC System, announces the publication of data that shows the promise of CTCs as a prognostic biomarker for patients with prostate cancer receiving novel therapies such as radium-223. The paper, “Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer,” was published in JCO Precision Oncology (DOI 10.1200/PO.23.00230).

Key Points: 
  • The paper, “Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer,” was published in JCO Precision Oncology (DOI 10.1200/PO.23.00230 ).
  • “Radium-223 is a valuable treatment option for patients with mCRPC, but better biomarkers are needed to identify patients most likely to benefit from therapy.
  • Additionally, imaging assessment in patients with bone-predominant disease has also been limited in patients receiving radium-223.
  • Upon controlling for known prognostic markers, PSA and tAP, the presence of baseline CTC AR-V7 expression was most predictive of OS among patients receiving radium-223.

SeekIn Presents New OncoSeek® Data at the AACR Annual Meeting in San Diego

Retrieved on: 
星期一, 四月 8, 2024
Diagnosis, DOI, Cohort (statistics), Patient, SAN, Artificial intelligence, Cancer, PTM, Doctor of Philosophy, MD, AACR, POC, Blood, Probability, Medical imaging

SAN DIEGO, April 8, 2024 /PRNewswire/ -- SeekIn Inc., a leader in blood-based cancer early detection and monitoring technology, today announced three additional validation studies that evaluate OncoSeek's ability to detect more than nine cancer types and predict the tissue of origin with a tube of blood. The data further validate the performance of OncoSeek with consistent results between the three new cohorts and the three previous cohorts of ~12,000 participants from China, the United States and Brazil. The results from three different platforms and two sample types indicate the generalization of OncoSeek's capability for common protein marker platforms. The findings were presented at the session entitled 'Multi-Cancer Early Detection Testing: Where Are We?' at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, one of the most significant oncology conferences highlighting the work of the best minds in cancer research from institutions all over the world.

Key Points: 
  • The results from three different platforms and two sample types indicate the generalization of OncoSeek's capability for common protein marker platforms.
  • The findings were presented at the session entitled 'Multi-Cancer Early Detection Testing: Where Are We?'
  • at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, one of the most significant oncology conferences highlighting the work of the best minds in cancer research from institutions all over the world.
  • With the demonstrated performance of OncoSeek on retrospective and prospective cohorts, SeekIn is pursuing additional prospective studies to evaluate performance in different applications.

RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury

Retrieved on: 
星期三, 三月 20, 2024
OTC Markets Group, Neurogenic bladder dysfunction, Death, Ampakine, DOI, Tetraplegia, Rat, Incidence, Bourbeau, Risk, Bruise, Patient, Research, University, Bladder cancer, Quality of life, Pleasure, EMG, Alom, Catheter, AMPA, Injury, Interim, CSO, Bangladesh Technical Education Board, Urinary tract infection, Respiration, Animal, Kidney, SCI, Rana, RespireRx

Restoration of bladder function is ranked as one of the highest priorities by individuals with SCI (Bourbeau et al., Spinal Cord 58:1216–1226; 2020).

Key Points: 
  • Restoration of bladder function is ranked as one of the highest priorities by individuals with SCI (Bourbeau et al., Spinal Cord 58:1216–1226; 2020).
  • Current treatment approaches usually require interventions such as catheterization for urinary voiding, which have their own set of risks and potentially significant set of complications.
  • The present paper, entitled “Acute ampakines increase voiding function and coordination in a rat model of SCI” (Rana, Alom et al.
  • We believe that this research has the potential to represent a novel, breakthrough in the treatment of SCI, which is badly needed.”